<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03179384</url>
  </required_header>
  <id_info>
    <org_study_id>16-AOI-02</org_study_id>
    <nct_id>NCT03179384</nct_id>
  </id_info>
  <brief_title>Impact on the Intestinal Microbiota of Treatment With Ceftriaxone in Women's Acute Community Pyelonephritis</brief_title>
  <acronym>CEFIMPACT</acronym>
  <official_title>Impact on the Intestinal Microbiota of Treatment With Ceftriaxone in Women's Acute Community Pyelonephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute pyelonephritis (APN) corresponds to infections of the renal parenchyma. The annual&#xD;
      incidence of these infections is estimated at 4-6 million cases in France, with 60 to 90% of&#xD;
      patients managed in general city medicine. The ceftriaxone, parenteral third-generation&#xD;
      cephalosporin (C3G), occupies an important place in the antibiotic treatment of these&#xD;
      infections: this is the recommended probabilistic treatment, and in some situations the&#xD;
      treatment can be continued in its entirety via a Ceftriaxone monotherapy.&#xD;
&#xD;
      The aim of the last antibiotic plan is to avoid the use of antibiotic therapies with a high&#xD;
      selection capacity (cephalosporins, penicillins, fluoroquinolones, etc.) and thus reduce the&#xD;
      incidence and prolongation over time of the digestive carriage of multi-resistant bacteria .&#xD;
&#xD;
      To date, there have been few studies evaluating the impact of ceftriaxone on the emergence of&#xD;
      multi-resistant bacteria on an individual scale, with rather heterogeneous results (13-86%&#xD;
      C3G resistance).&#xD;
&#xD;
      Thus, before considering randomized studies comparing the ecological impact of different&#xD;
      molecules or therapeutic regimens in the treatment of ANP, it is necessary to have a precise&#xD;
      and rigorous evaluation of the ecological impact of the molecule reference in this&#xD;
      indication.&#xD;
&#xD;
      The investigators propose a study to evaluate the impact on the digestive flora at 1 month of&#xD;
      a ceftriaxone antibiotic therapy (7 days) in the management of acute pyelonephritis in women.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 26, 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Emergence of ceftriaxone-resistant Enterobacteriaceae</measure>
    <time_frame>at 28 days</time_frame>
    <description>The emergence of ceftriaxone-resistant Enterobacteriaceae at 28 days after cessation of treatment on rectal swab.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pyelonephritis Acute</condition>
  <arm_group>
    <arm_group_label>ceftriaxone treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftriaxone</intervention_name>
    <description>ceftriaxone (1g intravenous or 1g/35mL intramuscular) will be given to patients during 7 days</description>
    <arm_group_label>ceftriaxone treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Over 18 years old&#xD;
&#xD;
          -  Admitted to the emergency department with a diagnosis of PNA (simple or at risk of&#xD;
             complications, without signs of seriousness)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to ceftriaxone, to another cephalosporin or to any of the excipients&#xD;
&#xD;
          -  A history of severe hypersensitivity (eg anaphylactic reaction) to another class of&#xD;
             antibacterial agent in the beta-lactam family (penicillins, monobatams and&#xD;
             carbapenems)&#xD;
&#xD;
          -  Severe pyelonephritis, including obstructive APN&#xD;
&#xD;
          -  Pyelonephritis in patients with a urinary catheter&#xD;
&#xD;
          -  Antibiotic treatment in the previous 6 months&#xD;
&#xD;
          -  Chronic dialysis patient&#xD;
&#xD;
          -  Patient with hepatic impairment&#xD;
&#xD;
          -  Pregnancy or breast-feeding in progress&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisa DEMONCHY, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisa DEMONCHY, MD</last_name>
    <phone>492035462</phone>
    <phone_ext>+33</phone_ext>
    <email>demonchy.e@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa DEMONCHY, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>May 29, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyelonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftriaxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

